Ani Pharmaceuticals (ANIP) EBIT Margin (2011 - 2026)

Ani Pharmaceuticals has disclosed EBIT Margin across 16 years of filings, most recently posting 15.21% for Q2 2026.

• In Q2 2026, EBIT Margin rose 864.0% year-over-year to 15.21%; the TTM figure through Jun 2026 stood at 15.37% (up 1334.0% YoY), while the FY2025 annual figure was 12.58%, up 1248.0% from the prior year.
• EBIT Margin came in at 15.21% for Q2 2026 at Ani Pharmaceuticals, down from 16.38% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 16.38% in Q1 2026 to a low of 29.77% in Q1 2022.
• Average EBIT Margin over 5 years is 3.95%, with a median of 7.92% recorded in 2025.
• The largest YoY upside for EBIT Margin was 4087 bps in 2022 against a maximum downside of 3536 bps in 2022.
• Over 5 years, EBIT Margin stood at 1.93% in 2022, then surged by 165 bps to 5.11% in 2023, then tumbled by 145 bps to 2.3% in 2024, then soared by 713 bps to 14.07% in 2025, then increased by 8 bps to 15.21% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 15.21% in Q2 2026, 16.38% in Q1 2026, and 14.07% in Q4 2025.